762P Pamiparib combined with surufatinib as a neoadjuvant therapy for advanced ovarian cancer patients in the entire population: Preliminary results of a prospective, exploratory, single-arm phase II clinical study

医学 临床终点 内科学 揭穿 人口 卵巢癌 肿瘤科 外科 化疗 临床研究阶段 不利影响 癌症 临床试验 环境卫生
作者
Bing Xia,Wen Jiang,J. Paul Chen,Yun-Fei Chen,Shan Wu,Wenbin Shen,Yaping Tian,Yun-Fei Chen,Xiaohong Chen,Weiqing Wu,Yuguang Ma,Jing Wang,Wei‐Xiang Qi,Zhonghua Wang,Xiangcheng Li,Xingxing Huang,Lin H,Bin Hong,Hebing Zhou
出处
期刊:Annals of Oncology [Elsevier]
卷期号:34: S520-S520
标识
DOI:10.1016/j.annonc.2023.09.1941
摘要

Optimal tumor reduction surgery is crucial for for advanced ovarian cancer (OC) prognosis. Neoadjuvant chemotherapy can increase surgery chances for OC, but the benefit to patients (pts) is limited. PARP inhibitors combined with anti-angiogenic drugs have significant benefits in the first-line maintenance and recurrence treatment of OC. This study aims to evaluate the efficacy and safety of Pamiparib combined with Surufatinib neoadjuvant therapy (NAT) for advanced unresectable OC in the entire population. This is a single-center, single-arm, phase II study following Simon's two-stage design. 20 pts with newly diagnosed unresectable (Fagotti score ≥ 8 or upper abdominal CT score ≥ 3) FIGO III-IV OC were recruited. Enrolled pts will receive NAT with Pamiparib (40 mg bid q3w for 3 cycles) combined with Surufatinib (250mg bid q3w for 2 cycles), followed by interval debulking surgery (IDS) and4 cycles of platinum-containing chemotherapy. The primary endpoint is complete resection rate (R0), and secondary endpoints include objective response rate (ORR), pathologic complete response(pCR) rate, progression-free survival, overall survival, and safety. As of Aug 30, 2023, of the 20 enrolled pts, 16 had completed genetic testing, and 14 were homologous recombination deficiency (HRD) positive, with 9 cases of BRCA1/2 mutations. By Aug 30, 2023, 17 pts completed NAT and IDS with an ORR of 100%. 15 pts achieved R0 surgery (88.24%), and 2 pts achieved R1. All 20 pts were evaluable by GCIG CA125 criteria, and CA125 response was all observed (100%). Grade 3 or 4 treatment-related adverse events that occurred are neutropenia, thrombocytopenia, anemia, and hepatic dysfunction. Pamiparib combined with Surufatinib as a new neoadjuvant "chemotherapy-free" regimen showed extremely high R0 and ORR rates with manageable toxicity profiles. Currently, the experiment is still ongoing and further analysis and reporting of more data will be conducted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吃小孩的妖怪完成签到 ,获得积分10
1秒前
啊嚯发布了新的文献求助10
3秒前
等待戈多完成签到,获得积分10
7秒前
科研通AI2S应助啊啊啊啊采纳,获得10
8秒前
英姑应助啊啊啊啊采纳,获得10
8秒前
科研通AI2S应助啊啊啊啊采纳,获得10
8秒前
科研通AI2S应助啊啊啊啊采纳,获得10
8秒前
FashionBoy应助啊啊啊啊采纳,获得10
8秒前
皮卡丘完成签到 ,获得积分0
14秒前
Lau完成签到 ,获得积分10
15秒前
丹尼完成签到 ,获得积分10
18秒前
蓝眸完成签到 ,获得积分10
24秒前
康复小白完成签到 ,获得积分10
24秒前
nhzz2023完成签到 ,获得积分0
27秒前
dhjic完成签到 ,获得积分10
30秒前
轩辕剑身完成签到,获得积分10
32秒前
一只小陈陈完成签到,获得积分10
34秒前
mojomars完成签到,获得积分10
40秒前
47秒前
浩浩完成签到 ,获得积分10
47秒前
trussie发布了新的文献求助10
52秒前
求文完成签到,获得积分10
54秒前
祈祈完成签到 ,获得积分10
58秒前
lixinyue完成签到 ,获得积分10
1分钟前
pp完成签到,获得积分10
1分钟前
共享精神应助zoloft采纳,获得10
1分钟前
ko1完成签到 ,获得积分10
1分钟前
1分钟前
Young完成签到 ,获得积分10
1分钟前
Mark完成签到 ,获得积分10
1分钟前
王敏完成签到 ,获得积分10
1分钟前
zoloft发布了新的文献求助10
1分钟前
jie完成签到 ,获得积分10
1分钟前
都要多喝水完成签到,获得积分10
1分钟前
黄花完成签到 ,获得积分10
1分钟前
花花糖果完成签到 ,获得积分10
1分钟前
XC完成签到 ,获得积分10
1分钟前
啊啊啊啊完成签到,获得积分10
1分钟前
京京完成签到 ,获得积分10
1分钟前
向雫完成签到 ,获得积分10
1分钟前
高分求助中
Sustainability in Tides Chemistry 1500
Handbook of the Mammals of the World – Volume 3: Primates 805
拟南芥模式识别受体参与调控抗病蛋白介导的ETI免疫反应的机制研究 550
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Manual of Sewer Condition Classification 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3068290
求助须知:如何正确求助?哪些是违规求助? 2722176
关于积分的说明 7476094
捐赠科研通 2369177
什么是DOI,文献DOI怎么找? 1256228
科研通“疑难数据库(出版商)”最低求助积分说明 609524
版权声明 596835